{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:07:28Z","timestamp":1770250048125,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82500274"],"award-info":[{"award-number":["82500274"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470196"],"award-info":[{"award-number":["82470196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Incubation Program for Clinical Trials","award":["19HXFH030"],"award-info":[{"award-number":["19HXFH030"]}]},{"name":"Achievement Transformation Project","award":["CGZH21001"],"award-info":[{"award-number":["CGZH21001"]}]},{"name":"1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University","award":["ZYJC21007"],"award-info":[{"award-number":["ZYJC21007"]}]},{"name":"Translational Research Grant of NCRCH","award":["2021WWB03"],"award-info":[{"award-number":["2021WWB03"]}]},{"name":"Chengdu Science and Technology Program","award":["2022-YF05-01444-SN"],"award-info":[{"award-number":["2022-YF05-01444-SN"]}]},{"DOI":"10.13039\/501100018525","name":"Key Research and Development Program of Sichuan Province","doi-asserted-by":"publisher","award":["2023YFS0031"],"award-info":[{"award-number":["2023YFS0031"]}],"id":[{"id":"10.13039\/501100018525","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2502600"],"award-info":[{"award-number":["2022YFC2502600"]}]},{"name":"Sichuan University Faculty Start Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-04166-2","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:08:30Z","timestamp":1767780510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rho-related GTP-binding protein RhoE (RND3) regulates multiple myeloma bone disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Qianwen","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyue","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haonan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingcao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"4166_CR1","doi-asserted-by":"publisher","unstructured":"Rafae F, van Rhee, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma, The Oncologist, vol. 29, no. 3, pp. 200\u2013212, Mar. 2024, https:\/\/doi.org\/10.1093\/oncolo\/oyad306","DOI":"10.1093\/oncolo\/oyad306"},{"issue":"1","key":"4166_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333. https:\/\/doi.org\/10.4065\/78.1.21.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"4166_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","volume":"42","author":"M Edwards","year":"2008","unstructured":"Edwards M, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone. 2008;42(6):1007\u201313. https:\/\/doi.org\/10.1016\/j.bone.2008.01.027.","journal-title":"Bone"},{"issue":"4","key":"4166_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","volume":"49","author":"T Taube","year":"1992","unstructured":"Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol. 1992;49(4):192\u20138. https:\/\/doi.org\/10.1111\/j.1600-0609.1992.tb00046.x.","journal-title":"Eur J Haematol"},{"issue":"2","key":"4166_CR5","first-page":"76","volume":"14","author":"EC Papadopoulou","year":"2010","unstructured":"Papadopoulou EC, Batzios SP, Dimitriadou M, Perifanis V, Garipidou V. Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches. Hippokratia. 2010;14(2):76\u201381.","journal-title":"Hippokratia"},{"issue":"4","key":"4166_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000443275","volume":"168","author":"R Vyzoukaki","year":"2015","unstructured":"Vyzoukaki R, Tsirakis G, Pappa CA, Devetzoglou M, Tzardi M, Alexandrakis MG. The impact of mast cell density on the progression of bone disease in multiple myeloma patients. Int Arch Allergy Immunol. 2015;168(4):263\u20138. https:\/\/doi.org\/10.1159\/000443275.","journal-title":"Int Arch Allergy Immunol"},{"issue":"14","key":"4166_CR7","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","volume":"133","author":"E Terpos","year":"2019","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133(14):1534\u20139. https:\/\/doi.org\/10.1182\/blood-2018-11-852459.","journal-title":"Blood"},{"key":"4166_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.153999","volume":"101","author":"SN Dankel","year":"2019","unstructured":"Dankel SN, et al. The Rho GTPase RND3 regulates adipocyte lipolysis. Metabolism. 2019;101:153999. https:\/\/doi.org\/10.1016\/j.metabol.2019.153999.","journal-title":"Metabolism"},{"issue":"18","key":"4166_CR9","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1128\/MCB.24.18.7829-7840.2004","volume":"24","author":"P Villalonga","year":"2004","unstructured":"Villalonga P, Guasch RM, Riento K, Ridley AJ. RhoE inhibits cell cycle progression and Ras-induced transformation. Mol Cell Biol. 2004;24(18):7829\u201340. https:\/\/doi.org\/10.1128\/MCB.24.18.7829-7840.2004.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"4166_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1042\/BJ20111517","volume":"442","author":"H Luo","year":"2012","unstructured":"Luo H, Zou J, Dong Z, Zeng Q, Wu D, Liu L. Up-regulated miR-17 promotes cell proliferation, tumour growth and cell cycle progression by targeting the RND3 tumour suppressor gene in colorectal carcinoma. Biochem J. 2012;442(2):311\u201321. https:\/\/doi.org\/10.1042\/BJ20111517.","journal-title":"Biochem J"},{"issue":"11","key":"4166_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1158\/1541-7786.MCR-16-0164","volume":"14","author":"L Paysan","year":"2016","unstructured":"Paysan L, Piquet L, Saltel F, Moreau V. Rnd3 in cancer: a review of the evidence for tumor promoter or suppressor. Mol Cancer Res. 2016;14(11):1033\u201344. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0164.","journal-title":"Mol Cancer Res"},{"issue":"18","key":"4166_CR12","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1158\/1078-0432.CCR-09-0911","volume":"15","author":"MS Arredouani","year":"2009","unstructured":"Arredouani MS, et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res. 2009;15(18):5794\u2013802. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0911.","journal-title":"Clin Cancer Res"},{"key":"4166_CR13","unstructured":"Home - GEO - NCBI. Accessed: Jun. 17, 2024. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/geo\/"},{"key":"4166_CR14","doi-asserted-by":"publisher","unstructured":"Cui Y et al. Apr., Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease, J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res., vol. 37, no. 4, pp. 711\u2013723, 2022, https:\/\/doi.org\/10.1002\/jbmr.4507","DOI":"10.1002\/jbmr.4507"},{"issue":"Pt 2","key":"4166_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1042\/BJ20040058","volume":"381","author":"K Ogawa","year":"2004","unstructured":"Ogawa K, Chen F, Kuang C, Chen Y. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-\u03b2 is mediated by a nuclear factor-\u03baB site. Biochem J. 2004;381(Pt 2):413\u201322. https:\/\/doi.org\/10.1042\/BJ20040058.","journal-title":"Biochem J"},{"issue":"5","key":"4166_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/10520295.2016.1179342","volume":"91","author":"D Otali","year":"2016","unstructured":"Otali D, Fredenburgh J, Oelschlager DK, Grizzle WE. A standard tissue as a control for histochemical and immunohistochemical staining. Biotech Histochem. 2016;91(5):309\u201326. https:\/\/doi.org\/10.1080\/10520295.2016.1179342.","journal-title":"Biotech Histochem"},{"key":"4166_CR17","unstructured":"UniProt. UniProt. Accessed: Jun. 12, 2025. [Online]. Available: https:\/\/www.uniprot.org"},{"issue":"8016","key":"4166_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493\u2013500. https:\/\/doi.org\/10.1038\/s41586-024-07487-w.","journal-title":"Nature"},{"issue":"1","key":"4166_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/cphy.c150018","volume":"6","author":"W Jie","year":"2015","unstructured":"Jie W, Andrade KC, Lin X, Yang X, Yue X, Chang J. Pathophysiological functions of Rnd3\/RhoE. Compr Physiol. 2015;6(1):169\u201386. https:\/\/doi.org\/10.1002\/cphy.c150018.","journal-title":"Compr Physiol"},{"key":"4166_CR20","doi-asserted-by":"publisher","DOI":"10.4161\/sgtp.29846","volume":"5","author":"L Julian","year":"2014","unstructured":"Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014;5:e29846. https:\/\/doi.org\/10.4161\/sgtp.29846.","journal-title":"Small GTPases"},{"issue":"1","key":"4166_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1165\/rcmb.2002-0206OC","volume":"29","author":"HW Liu","year":"2003","unstructured":"Liu HW, et al. The RhoA\/Rho kinase pathway regulates nuclear localization of serum response factor. Am J Respir Cell Mol Biol. 2003;29(1):39\u201347. https:\/\/doi.org\/10.1165\/rcmb.2002-0206OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"4166_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00216-9","volume":"5","author":"S Shan","year":"2024","unstructured":"Shan S, et al. Y-27632 targeting ROCK1&2 modulates cell growth, fibrosis and epithelial-mesenchymal transition in hyperplastic prostate by inhibiting \u03b2-catenin pathway. Mol Biomed. 2024;5(1):52. https:\/\/doi.org\/10.1186\/s43556-024-00216-9.","journal-title":"Mol Biomed"},{"key":"4166_CR23","doi-asserted-by":"publisher","unstructured":"Shin D, et al. Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma. Haematologica. Jul. 2024;109(7):2207\u201318. https:\/\/doi.org\/10.3324\/haematol.2023.283784.","DOI":"10.3324\/haematol.2023.283784"},{"issue":"9","key":"4166_CR24","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324. https:\/\/doi.org\/10.1002\/ajh.27422.","journal-title":"Am J Hematol"},{"issue":"18","key":"4166_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159527","volume":"132","author":"D Gai","year":"2022","unstructured":"Gai D, et al. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022;132(18):e159527. https:\/\/doi.org\/10.1172\/JCI159527.","journal-title":"J Clin Invest"},{"issue":"18","key":"4166_CR26","doi-asserted-by":"publisher","first-page":"7760","DOI":"10.7150\/thno.76852","volume":"12","author":"R Liu","year":"2022","unstructured":"Liu R, et al. m6A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease. Theranostics. 2022;12(18):7760\u201374. https:\/\/doi.org\/10.7150\/thno.76852.","journal-title":"Theranostics"},{"issue":"23","key":"4166_CR27","doi-asserted-by":"publisher","first-page":"6901","DOI":"10.1158\/0008-5472.CAN-16-0517","volume":"76","author":"L Xu","year":"2016","unstructured":"Xu L, et al. Cell adhesion molecule CD166 drives malignant progression and osteolytic disease in multiple myeloma. Cancer Res. 2016;76(23):6901\u201310. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0517.","journal-title":"Cancer Res"},{"key":"4166_CR28","doi-asserted-by":"publisher","unstructured":"Wawrzyniak, Balawender K. Structural and Metabolic Changes in Bone, Anim. Open Access J. MDPI, vol. 12, no. 15, p. 1946, Jul. 2022. https:\/\/doi.org\/10.3390\/ani12151946","DOI":"10.3390\/ani12151946"},{"issue":"5","key":"4166_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jobcr.2023.06.002","volume":"13","author":"Khoswanto","year":"2023","unstructured":"Khoswanto. Role of matrix metalloproteinases in bone regeneration: narrative review. J Oral Biol Craniofac Res. 2023;13(5):539\u201343. https:\/\/doi.org\/10.1016\/j.jobcr.2023.06.002.","journal-title":"J Oral Biol Craniofac Res"},{"issue":"4","key":"4166_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2174\/1389201021666200630140735","volume":"22","author":"L Kou","year":"2021","unstructured":"Kou L, et al. Matrix Metalloproteinase Inspired Therapeutic Strategies for Bone Diseases. Curr Pharm Biotechnol. 2021;22(4):451\u201367. https:\/\/doi.org\/10.2174\/1389201021666200630140735.","journal-title":"Curr Pharm Biotechnol"},{"key":"4166_CR31","doi-asserted-by":"publisher","unstructured":"Paiva KBS, Granjeiro JM. Chapter Six - Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair, in Progress in Molecular Biology and Translational Science, vol. 148, R. A. Khalil, Ed., in Matrix Metalloproteinases and Tissue Remodeling in Health and Disease: Target Tissues and Therapy, vol. 148., Academic Press, 2017, pp. 203\u2013303. https:\/\/doi.org\/10.1016\/bs.pmbts.2017.05.001","DOI":"10.1016\/bs.pmbts.2017.05.001"},{"key":"4166_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1127407","volume":"13","author":"Y-Y Li","year":"2023","unstructured":"Li Y-Y, Zhang L-Y, Xiang Y-H, Li D, Zhang J. Matrix metalloproteinases and tissue inhibitors in multiple myeloma: promote or inhibit? Front Oncol. 2023;13:1127407. https:\/\/doi.org\/10.3389\/fonc.2023.1127407.","journal-title":"Front Oncol"},{"issue":"26","key":"4166_CR33","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483\u201394. https:\/\/doi.org\/10.1056\/NEJMoa030847.","journal-title":"N Engl J Med"},{"issue":"4","key":"4166_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cdt3.35","volume":"8","author":"F Zhang","year":"2022","unstructured":"Zhang F, Zhuang J. Pathophysiology and therapeutic advances in myeloma bone disease. Chronic Dis Transl Med. 2022;8(4):264\u201370. https:\/\/doi.org\/10.1002\/cdt3.35.","journal-title":"Chronic Dis Transl Med"},{"issue":"6","key":"4166_CR35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","volume":"80","author":"M Kaiser","year":"2008","unstructured":"Kaiser M, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol. 2008;80(6):490\u20134. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01065.x.","journal-title":"Eur J Haematol"},{"issue":"3","key":"4166_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/ejh.12239","volume":"92","author":"M Alegre","year":"2014","unstructured":"Alegre M, Gironella A, Bail\u00e9n A, Giraldo P. Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. Eur J Haematol. 2014;92(3):181\u20138. https:\/\/doi.org\/10.1111\/ejh.12239.","journal-title":"Eur J Haematol"},{"issue":"1","key":"4166_CR37","first-page":"30","volume":"6","author":"R Ria","year":"2013","unstructured":"Ria R, Reale A, Moschetta M, Mangialardi G, Dammacco F, Vacca A. A retrospective study of skeletal and disease-free survival benefits of Zoledronic acid therapy in patients with multiple myeloma treated with novel agents. Int J Clin Exp Med. 2013;6(1):30\u20138.","journal-title":"Int J Clin Exp Med"},{"issue":"3","key":"4166_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2217\/fon-2017-0403","volume":"14","author":"J Yee","year":"2018","unstructured":"Yee J, Raje NS. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. Future Oncol. 2018;14(3):195\u2013203. https:\/\/doi.org\/10.2217\/fon-2017-0403.","journal-title":"Future Oncol"},{"issue":"3","key":"4166_CR39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(18)30072-X.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4166_CR40","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125\u201332. https:\/\/doi.org\/10.1200\/JCO.2010.31.3304.","journal-title":"J Clin Oncol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-04166-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04166-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04166-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:05:26Z","timestamp":1770203126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-025-04166-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4166"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-04166-2","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of the samples was approved by the Ethical Committee of West China Hospital, Sichuan University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}